HDAC inhibitors (inhibiting targets of signaling pathways) used for various assays, some have entered clinical trials, which would be new cancer therapies.
Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations Sijie Chen, Tong Lin, Ruchira Basu, Jeremy Ritchey, Shen Wang, Yichuan Luo, Xingcan Li, Dehua Pei, Levent Burak Kara & Xiaolin Cheng Nat Commun 15, 1611 (2024) • code Deep-learning...
例如:EGFR抑制剂(爱必妥)治疗转移性结直肠癌,如果患者为K-ras突变型,在化疗中加入爱必妥并不能增加疗效,反而使得患者遭遇爱必妥额外的副作用。加之目前绝大多数靶向药物价格昂贵,选择最可能获益的患者接受分子靶向治疗也更加符合卫生经济学的要求。因此,分子靶向治疗更加需要个体化开展。分子肿瘤学和分子遗传学研究的发展...
Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see CLINICAL PHARMACOLOGY]. Intervention: St. John’s Wort, rifampin: Avoid concomitant use with DEXILANT. Ritonavir-containing products: See prescribing information. CYP2C19 or CYP3A4 Inhibitors Clinical Im...
Dose modification, when administered with encorafenib, is NOT recommended for palmar-plantar erythrodysesthesia syndrome (PPES), noncutaneous RAS mutation-positive malignancies, and QTc prolongation Recurrent Grade 2 or first occurrence of any Grade 3 Withhold for up to 4 weeks; if improves to ...
图 3 :豹斑综合征的牛奶咖啡斑及雀斑 此外,努南综合征、斑驳病、范可尼贫血、RAS基因相关疾病、Bloom综合征等也可能伴随多发性牛奶咖啡斑。 ** 牛奶咖啡斑与神经纤维瘤病的关系** 牛奶咖啡斑是1型神经纤维瘤病最常见且最早出现的症状。但对于2型神经纤维瘤病,牛奶咖啡斑并不常见,即使有,数量也较少,且周围...
在RET野生型的病人中,18%～80%具有体细胞RAS突变。另外,血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)也在MTC肿瘤细胞中高表达[34]。众多酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI)药物涵盖了MTC的治疗靶点,并在晚期MTC中进行了多项临床试验。然而,目前有Ⅲ期随机对照临床试验证据...
Inhibitors of histone demethylases United States Patent 9611219 Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the ...
Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvat...
Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways United States Patent 10869872 Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing ...